A comparative study of radiomics and deep-learning based methods for pulmonary nodule malignancy prediction in low dose CT images
File(s)737368_Manuscript.PDF (1.51 MB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Objectives: Both radiomics and deep learning methods have shown great promise in predicting lesion malignancy in various
image-based oncology studies. However, it is still unclear which method to choose for a specific clinical problem given the access to
the same amount of training data. In this study, we try to compare the performance of a series of carefully selected conventional
radiomics methods, end-to-end deep learning models, and deep-feature based radiomics pipelines for pulmonary nodule malignancy
prediction on an open database that consists of 1297 manually delineated lung nodules.
Methods: Conventional radiomics analysis was conducted by extracting standard handcrafted features from target nodule images.
Several end-to-end deep classifier networks, including VGG, ResNet, DenseNet, and EfficientNet were employed to identify lung
nodule malignancy as well. In addition to the baseline implementations, we also investigated the importance of feature selection
and class balancing, as well as separating the features learned in the nodule target region and the background/context region. By
pooling the radiomics and deep features together in a hybrid feature set, we investigated the compatibility of these two sets
with respect to malignancy prediction.
Results: The best baseline conventional radiomics model, deep learning model, and deep-feature based radiomics model achieved
AUROC values (mean±standard deviations) of 0.792±0.025, 0.801±0.018, and 0.817±0.032, respectively through 5-fold crossvalidation analyses. However, after trying out several optimization techniques, such as feature selection and data balancing, as
well as adding context features, the corresponding best radiomics, end-to-end deep learning, and deep-feature based models
achieved AUROC values of 0.921±0.010, 0.824±0.021, and 0.936±0.011, respectively. We achieved the best prediction accuracy from
the hybrid feature set (AUROC: 0.938±0.010).
Conclusion: The end-to-end deep-learning model outperforms conventional radiomics out of the box without much fine-tuning. On
the other hand, fine-tuning the models lead to significant improvements in the prediction performance where the conventional and
deep-feature based radiomics models achieved comparable results. The hybrid radiomics method seems to be the most promising
model for lung nodule malignancy prediction in this comparative study.
image-based oncology studies. However, it is still unclear which method to choose for a specific clinical problem given the access to
the same amount of training data. In this study, we try to compare the performance of a series of carefully selected conventional
radiomics methods, end-to-end deep learning models, and deep-feature based radiomics pipelines for pulmonary nodule malignancy
prediction on an open database that consists of 1297 manually delineated lung nodules.
Methods: Conventional radiomics analysis was conducted by extracting standard handcrafted features from target nodule images.
Several end-to-end deep classifier networks, including VGG, ResNet, DenseNet, and EfficientNet were employed to identify lung
nodule malignancy as well. In addition to the baseline implementations, we also investigated the importance of feature selection
and class balancing, as well as separating the features learned in the nodule target region and the background/context region. By
pooling the radiomics and deep features together in a hybrid feature set, we investigated the compatibility of these two sets
with respect to malignancy prediction.
Results: The best baseline conventional radiomics model, deep learning model, and deep-feature based radiomics model achieved
AUROC values (mean±standard deviations) of 0.792±0.025, 0.801±0.018, and 0.817±0.032, respectively through 5-fold crossvalidation analyses. However, after trying out several optimization techniques, such as feature selection and data balancing, as
well as adding context features, the corresponding best radiomics, end-to-end deep learning, and deep-feature based models
achieved AUROC values of 0.921±0.010, 0.824±0.021, and 0.936±0.011, respectively. We achieved the best prediction accuracy from
the hybrid feature set (AUROC: 0.938±0.010).
Conclusion: The end-to-end deep-learning model outperforms conventional radiomics out of the box without much fine-tuning. On
the other hand, fine-tuning the models lead to significant improvements in the prediction performance where the conventional and
deep-feature based radiomics models achieved comparable results. The hybrid radiomics method seems to be the most promising
model for lung nodule malignancy prediction in this comparative study.
Date Acceptance
2021-11-29
Citation
Frontiers in Oncology, 11
ISSN
2234-943X
Publisher
Frontiers Media
Journal / Book Title
Frontiers in Oncology
Volume
11
Copyright Statement
© 2021 Astaraki, Yang, Zakko, Toma-Dasu, Smedby and Wang. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
License URL
Sponsor
British Heart Foundation
European Research Council Horizon 2020
Commission of the European Communities
Innovative Medicines Initiative
Boehringer Ingelheim Ltd
Medical Research Council (MRC)
Medical Research Council (MRC)
Identifier
https://www.frontiersin.org/articles/10.3389/fonc.2021.737368/full
Grant Number
PG/16/78/32402
H2020-SC1-FA-DTS-2019-1 952172
101005122
101005122
PO:4700244755 Study:1199-0457
MR/V023799/1
MC_PC_21013
Subjects
1112 Oncology and Carcinogenesis
Publication Status
Published